Major depressive disorder is a severe, disabling disorder that affects around 4.7% of the
population worldwide. Based on the monoaminergic hypothesis of depression, monoamine …

Serotonin, 5-hydroxytryptamine (5-HT), is one of the class of monoamine neurontransmitters,
all of which have a chemical template comprised of a basic amino group separated from an …

The neurotransmitter serotonin (5-hdroxytryptamine; 5-HT) has been implicated in the
pathophysiology and treatment of major depression since the serendipitous discovery of …

Although monoaminergic antidepressants revolutionized the treatment of Major Depressive
Disorder (MDD) over a half-century ago, approximately one third of depressed patients …

Major depression is a debilitating and recurrent disorder with a substantial lifetime risk and a
high social cost. Depressed patients generally display co-morbid symptoms, and depression …

Currently available antidepressants used to treat major depressive disorder (MDD)
unfortunately often take weeks to months to achieve their full effects, commonly resulting in …

Major depressive disorder is a common and disabling illness that leads to significant
reductions in quality of life and considerable cost to society. Despite numerous advances in …

Abstract Treatment resistance to the antidepressive pharmacotherapy represents one of the
most important clinical challenges in the pharmacological management of unipolar …

Objective: Current therapeutics of depression are similar in their time to antidepressant
action and often take weeks to months to achieve response and remission, which commonly …

There have been significant advances in the treatment of depression since the serendipitous
discovery that modulating monoaminergic neurotransmission may be a pathological …